Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.

Abstract

BACKGROUND:

Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy.

METHODS:

Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43). Plasma and urinary AGEs (N(ε)-(carboxymethyl) lysine [CML], N(ε)-(Carboxyethyl) lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) and plasma markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1], soluble E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and after 6 and 12 weeks.

RESULTS:

Compared to placebo, benfotiamine did not result in significant reductions in plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade inflammation.

CONCLUSIONS:

Benfotiamine for 12 weeks did not significantly affect intermediate pathways of hyperglycemia-induced vascular complications. TRIAL REGRISTRATION: ClinicalTrials.gov NCT00565318.

• Authors: Alaa Alkhalaf, Nanne Kleefstra, Klaas H Groenier, Henk J G Bilo, Reinold O B Gans, Peter Heeringa, Jean L Scheijen, Casper G Schalkwijk, Gerjan J Navis, Stephan J L Bakker
• Journal: PloS one (PLoS One) Vol. 7 Issue 7 Pg. e40427 ( 2012) ISSN: 1932-6203 [Electronic] United States
• PMID: 22792314 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Cell Adhesion Molecules
• Glycation End Products, Advanced
• Inflammation Mediators
• Thiamine
• benphothiamine

Topics

• Aged
• Biomarkers (blood, urine)
• Cell Adhesion Molecules (blood)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Diabetic Nephropathies (blood, drug therapy, urine)
• Endothelial Cells (metabolism, pathology)
• Endothelium (metabolism, pathology, physiopathology)
• Female
• Glycation End Products, Advanced (blood, urine)
• Humans
• Inflammation (blood, drug therapy, urine)
• Inflammation Mediators (blood)
• Male
• Middle Aged
• Thiamine (analogs & derivatives, pharmacology, therapeutic use)
• Treatment Outcome